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Supervised neuromuscular exercise prior to
hip and knee replacement: 12-month
clinical effect and cost-utility analysis
alongside a randomised controlled trial
Linda Fernandes1,2*, Ewa M. Roos3, Søren Overgaard1,4, Allan Villadsen1 and Rikke Søgaard5,6
Abstract
Background: There are indications of beneficial short-term effect of pre-operative exercise in reducing pain and
improving activity of daily living after total hip replacement (THR) and total knee replacement (TKR) surgery. Though,
information from studies conducting longer follow-ups and economic evaluations of exercise prior to THR and TKR is
needed. The aim of the study was to analyse 12-month clinical effect and cost-utility of supervised neuromuscular
exercise prior to THR and TKR surgery.
Methods: The study was conducted alongside a randomised controlled trial including 165 patients scheduled for
standard THR or TKR at a hospital located in a rural area of Denmark. The patients were randomised to replacement
surgery with or without an 8-week preoperative supervised neuromuscular exercise program (Clinical Trials registration
no.: NCT01003756). Clinical effect was measured with Hip disability and Osteoarthritis Outcome Score (HOOS) and Knee
injury and Osteoarthritis Outcome Score (KOOS). Quality adjusted life years (QALYs) were based on EQ-5D-3L and
Danish preference weights. Resource use was extracted from national registries and valued using standard tariffs
(2012-EUR). Incremental net benefit was analysed to estimate the probability for the intervention being cost
effective for a range of threshold values. A health care sector perspective was applied.
Results: HOOS/KOOS quality of life [8.25 (95% CI, 0.42 to 16.10)] and QALYs [0.04 (95% CI, 0.01 to 0.07)] were
statistically significantly improved. Effect-sizes ranged between 0.09-0.59 for HOOS/KOOS subscales. Despite
including an intervention cost of €326 per patient, there was no difference in total cost between groups [€132
(95% CI −3942 to 3679)]. At a threshold of €40,000, preoperative exercise was found to be cost effective at 84%
probability.
Conclusion: Preoperative supervised neuromuscular exercise for 8 weeks was found to be cost-effective in
patients scheduled for THR and TKR surgery at conventional thresholds for willingness to pay. One-year clinical
effects were small to moderate and favoured the intervention group, but only statistically significant for quality of
life measures.
Trial registration: ClinicalTrials.gov (NCT01003756) October 28, 2009.
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Background
Total hip and knee replacement (THR and TKR) surgery
are recognized treatments for pain relief in patients with
severe symptoms from hip or knee osteoarthritis (OA)
[1]. Nevertheless, one year after surgery up to 50% of pa-
tients undergoing THR and TKR may not experience
clinically important improvements in pain and activities
of daily living (ADL) [2, 3]. Supervised exercise has
shown to be effective treatment for reducing pain and
improving ADL in patients with OA [4–9]. It seems ex-
ercise at later stages of the disease, and prior to joint re-
placement surgery, also has beneficial results [10, 11].
However, before a new treatment strategy such as pre-
operative exercise is implemented, one key input into the
decision-making process is the effect and cost-effectiveness
of the strategy in question. Today, information on the
post-operative effect of exercise prior to surgery is sparse
and sufficiently powered studies with feasible interventions
and longer follow-ups along with high-quality economic
evaluations are warranted [11–15].
We previously conducted a randomised controlled
trial (RCT) evaluating an 8-week supervised neuromus-
cular exercise prior to THR and TKR [10, 16]. The study
showed overall improvements in favour of the exercise
group in ADL prior to surgery and at 6 weeks postoper-
atively. At 3 months postoperatively the effects were di-
minished [16]. Although demonstrating short-term
effects only, the addition of preoperative exercise may be
clinically important in early mobilisation and returning
to prior activities. Our aim with this study was to evalu-
ate one-year clinical effect and cost-utility of the super-
vised neuromuscular exercise programme prior to THR
and TKR. If supervised exercise prior to THR and TKR
is shown to be cost-effective, health policy decision
makers should consider changing the pre-operative care
trajectory to include supervised exercise prior to THR
and TKR.
Methods
Overview of study design and participants
165 patients were included between 4 January 2010 and
21 March 2011.[10, 16] Inclusion criteria were; ≥18 years
of age and scheduled for THR or TKR due to symptom-
atic OA. Exclusion criteria were; scheduled for bilateral
surgery, previous fractures in or adjacent to the joint, in-
flammatory arthritis and severe heart disease or neuro-
logic deficits. Included patients were randomly allocated
to the intervention group, i.e. supervised neuromuscular
exercise and preoperative educational package (EP); or
to the control group, i.e. EP alone (Fig. 1). The primary
outcome was the ADL subscale of the Hip disability and
Osteoarthritis Outcome Score (HOOS) and Knee injury
and Osteoarthritis Outcome Score (KOOS) [17–19].
Clinical effect was measured with HOOS and KOOS at
one year post-surgery. Assessments points were at baseline,
8 weeks (post-intervention), 15 weeks (6 weeks post-
surgery), 21 weeks (3 months post-surgery) and 61 weeks
(one year post-surgery). The economic evaluation was con-
ducted alongside the RCTand applied the health care sector
perspective, incorporating cost of health care services, in-
cluding cost of the exercise program. It took form of a cost-
utility analysis using Quality Adjusted Life Years (QALYs).
The time horizon was 61 weeks within the start and end
date of the study (4 January 2010 – 13 August 2012).
Intervention
The neuromuscular exercise programme was supervised
by a physiotherapist and focused on lower extremity mus-
cular control and quality of movement.[10, 16, 20, 21] It
consisted of three parts: warm-up, circuit programme and
cool-down. The majority of the exercises were weight-
bearing exercises imitating functions of daily living and
the patients learned how to control hip-knee-foot align-
ment in each exercise. Progression of exercise level was
guided by neuromuscular control and quality of the per-
formance (determined by the physiotherapist) and with
acceptable exertion (determined by the patient). The
programme was delivered in groups of 6–12 patients twice
weekly lasting 1 h per session at the Department of Re-
habilitation at Odense University Hospital, Svendborg, in
a rural part of Southern Denmark. An attendance of 12
sessions or more was considered good compliance.
The EP was standard preoperative information on the
operating procedure, expected postoperative progression
and a leaflet on various exercises [16]. All patients were
offered the EP.
Intervention cost
Valuation of formal care of the exercise program was
based on tariff-based costs for physiotherapy in primary
care (https://fysio.dk/globalassets/documents/raadgivn
ing/overenskomster/praksisoverenskomster/takster-for-
fysioterapi-oktober-2016.pdf ). The fees reflect the phys-
iotherapist’s wage, capital cost and expenses, e.g. rental
costs, use of equipment, dispensable material and electri-
city. Implementation cost of the exercise program was not
included. Costs for the 3-h patient education package
were not included as this was offered to all participants in
the trial. All monetary units were reported in 2012-EUR
with an exchange rate of DKK 7.45 to 1 EUR.
Health care utilisation and cost
Individual data was extracted from two national regis-
ters: The National Health Insurance Service Registry and
The Danish National Patient Register [22, 23]. The
former includes details about all services provided in pri-
mary care including national reimbursement fees [22].
Fernandes et al. BMC Musculoskeletal Disorders  (2017) 18:5 Page 2 of 11
Fig. 1 (See legend on next page.)
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The latter includes details about all contacts to hospitals
including diagnoses, procedures and diagnosis-related-
grouping casemix tariffs [23].
Patient expenses
Valuation of patients’ time and transport for attending
the exercise classes were included in a sensitivity ana-
lysis. Valuation of informal time (i.e. time spent by pa-
tients attending the exercise regimen) was based on a
human capital approach, for which the value of a per-
son’s time is reflected by wage rates (productivity loss).
The wage rate was estimated by applying age- and gen-
der matched national average gross income for year
2012 extracted from Statistics Denmark [24]. Informal
time for one exercise session was set to a fixed value of
1.25 h. Patients’ expenses for travelling to and from the
gym were calculated by using the national fees for travel
reimbursement for 2012 (DKK 3.80/km or €0.51/km)
times the distance (km) between the exercise facility and
patients’ homes.
Patient reported outcome measures
The HOOS and KOOS assesses pain, symptoms, ADL,
function in sport and recreation and knee related quality
of life in five separate subscales scored on a 0–100
(worst to best) scale [18, 19, 25, 26].
Utility was expressed as QALYs measured with the
generic outcome measure European Quality of Life 5-
Dimension 3-Level Health Outcome (EQ-5D-3L) [27].
Health state valuations from the Danish general popula-
tion were adopted [28].
Analysis
Baseline subject characteristics were summarised as
number (%) or mean (SD). QALYs were produced by
calculating the area under the curve of the EQ-5D-3L
utility scores from baseline and all follow-ups assuming
linear trend between observations. Visits and costing for
primary care were categorised based on care provider. In
hospital stay and costing for secondary care were cate-
gorised based on primary unit. All parameters were
tested for normality and distribution. Because of skewed
data all comparative analyses, including the net benefit,
were based on bootstrapped standard errors. Non-
parametric bootstrapping with 10,000 replications was
applied [29].
Group comparisons were based on intention-to-treat
analysis.[30] Since no interaction (group allocation
joint involved) was seen in the original RCT,[16] the
analyses did not adjust for hip or knee involvement.
One-year clinical effect was expressed as the between-
group mean difference [95% confidence interval (CI)]
of change values (61 weeks – baseline) and effect-size
(d = mean difference of change values/pooled baseline
standard deviation) of the five subscale scores of the
HOOS and KOOS. Analysis of linear regression was
used for between-group comparisons of QALYs and
costs and presented as between-group mean differences
(95% CI) over the time horizon. An adjustment for
baseline health utility was included in the analysis to
account for baseline imbalances in the estimation of
mean differential QALYs [31].
Handling of missing EQ-5D-3L utility scores was
based on comparison of complete item response and
two different imputation methods: last observation car-
ried forward (LOCF), in which missing values are im-
puted based on existing values, and linear trend at point
(LTAP), in which missing values are imputed by values
based on a linear regression model using nonmissing ob-
servations in the series to fit the regression. Analysis
comparing responders and non-responders was per-
formed for QALYs. Since imputed data using the LTAP
method showed the lowest mean difference estimate for
QALYs (Table 2), and thereby the lowest risk of overesti-
mating results, it was decided to be used in the analyses.
A significance level of 0.05 was used.
Cost-utility
The cost-utility analysis adopted a health care sector
perspective. We estimated the value for money of the
intervention by calculating the incremental net monet-
ary benefit using a range of hypothetical threshold
values for decision-makers’ willingness-to-pay for a unit
of effect [32]. The threshold values ranged from €0 to
€100,000. The net benefits were presented visually in
cost-effectiveness acceptability curves (CEAC). These
curves illustrate the probability that the intervention is
cost-effective compared to the control at various
(See figure on previous page.)
Fig. 1 Flow diagram of patients participating in this study. * Co-morbidities (n = 97). ◆ Previous fracture in or adjacent to the joint (n = 13) (1 knee).
◆ Inflammatory arthritis (n = 11) (5 knee). ◆ Revision arthroplasty (n = 7) (4 knee). ◆ Previously enrolled with another joint (n = 9) (7 knee).
◆ Unicompartemental replacement (knee) (n = 27). ◆ Bilateral procedure in same session or within 3 month (n = 16). ◆ Necrosis of the femoral
head (hip) (n = 6). ◆ Neurological disorders (n = 6), Hemiparesis (n = 2), Parkinsons Disorder (n = 2), Dementia (n = 2). ◆ Dysplasia of the femoral
head (n = 1). ◆ Possible cancer metastasis in proximal femur (n = 1). ** The Danish Healthcare System has a one month treatment guarantee.
Entering this study meant all patients accepting an additional wait of up to 5 weeks in comparison to the treatment guarantee. After randomization,
this additional wait applied only for patients randomized to the 8 week exercise intervention. The control group was operated on when
originally scheduled
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threshold values of willingness-to-pay for a QALY
gain. A willingness-to-pay of €40,000 per QALY gained
was used as the threshold indicating good value for
money [33, 34].
Sensitivity analyses
Four sensitivity analyses were performed to assess ro-
bustness of results for cost-utility and presented in the
CEAC.
1. Complete item response analysis leaving out
patients not filling in the EQ-5D-3L one or more
times during the follow-up period.
2. Per-protocol analysis including only patients who
complied to exercise.
3. Not adjusting analysis for the potentially skewed
baseline EQ-5D-3 L.
4. Including patients’ travel and time costs associated
with attending exercise.
Results
Overall, 92.1% of the observations of the HOOS or
KOOS and the EQ-5D-3L at the five assessment points
were complete. There were 122 (74%) complete item
responses for QALYs. There was no significant differ-
ence between number of patients with missing QALY
in the intervention (n = 21) and control group (n = 22)
(p = 0.75). Cost data had no missing values. Except for
the EQ-5D-3L, there were no differences at baseline.
Baseline characteristics are presented in Table 1. Five
patients did not go through THR or TKR surgery during
the 61 weeks. Reasons for declining surgery were:
intervention group, much improved after exercise (n = 1)
and no reason specified (n = 1); and control group, cancer
(n = 1), started to exercise on her own (n = 1) and anxious
about surgical procedure (n = 1).
Patient reported outcomes
The intervention was associated with a statistically sig-
nificant QALY gain of 0.04 (95% CI, 0.01 to 0.07). The
QALYs showed similar results for complete item
response, different imputation methods and unadjusted
analyses (Table 2). Mean differences at 61 weeks
favoured the exercise group for all HOOS/KOOS sub-
scales, however only significantly so for the quality of life
subscale [mean difference 8.25 points (95% CI, 0.42 to
16.10)] (Table 2). Effect-sizes for HOOS/KOOS subscales
ranged from 0.09 – 0.59 (Table 2).
Resource use
All patients in both groups attended the preoperative
education package prior to surgery. In total, 144 exercise
sessions were provided during the intervention period
with a mean of 7.7 patients per session. On average,
patients in the intervention group had attended the exer-
cise programme 13.1 times (Table 3). Sixty-two of the 84
patients in the intervention group (74%) displayed good
compliance.
The average number of health care visits in primary
and secondary care, including the number of inhospital
days was not significantly different between groups, with
the exception of visits with a chiropractor (Table 3). In
total, 4 and 36 visits with chiropractor were registered in
the intervention and control groups, respectively. 95% of
the visits in the subgroup “other” had visited the dentist.
None of the participants had visited psychologist funded
by the national health care system during the follow-up
period. Summarizing all inhospital days, 75% were to
orthopaedic units.
Cost
Participating in the supervised neuromuscular exercise
program cost on average (SE) €326 (12.9) per patient
(Table 4). A mean of 7.7 patients attended each session.
Hence, the tariff to the physiotherapist was based on
groups of eight equivalent to a cost of €186/session
(https://fysio.dk/praksis/Overenskomst-og-takster/Almen-
fysioterapi1/Almen-fysioterapi/). No differences between
groups (€-132; 95% CI −3668 to 3405) were found for
costs in primary or secondary health care sector (Table 4).
The largest cost was, as expected, found for inpatient
hospital stay.
Table 1 Baseline subject characteristics
Intervention
group
Control
group
Mean difference
(95%CI)
n 84 81
Female sex 47 (56%) 45 (56%)
Age–years 67.9 (8.6) 66.9 (8.3) 1.08 (−1.52 to 3.67)
BMI–kg/m2 29.6 (4.5) 31.1 (6.1) −1.41 (−3.05 to 0.24)
Waiting list THA 43 (51%) 41 (51%)
Waiting list TKA 41 (49%) 40 (49%)
EQ-5D-3L 0.63 (0.15) 0.57 (0.19) 0.06 (0.01 to 0.12)
HOOS/KOOS
ADL 50.5 (15.1) 45.6 (16.9) 4.9 (−0.02 to 9.83)
Pain 46.8 (14.3) 42.7 (14.4) 4.0 (−0.39 to 8.46)
Symptoms 49.4 (19.7) 44.6 (18.6) 4.8 (−0.98 to 10.55)
Sport & Recreation 24.6 (17.2) 19.9 (18.2) 4.6 (−0.80 to 10.09)
Quality of life 31.2 (12.1) 28.9 (15.9) 2.3 (−2.01 to 6.60)
Continuous variables are expressed as the mean (SD); non-continuous variables
are expressed as the number of patients (%); THA, Total hip arthroplasy; TKA, Total
knee arthroplasty; EQ5D-3L, European Quality of Life 5 Dimension 3 Level Health
Outcome; HOOS, Hip disability and Osteoarthritis Outcome Score; KOOS, Knee
injury and Osteoarthritis Outcome Score; ADL, function in daily living
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Patients attending exercise travelled on average
21.5 km (range 0.5–78.3 km) to the exercise facility and
had a mean (SE) transportation cost of €137 (12.2). The
mean (SE) informal time valuation was €302 (15.3) for
the intervention period. When including patients’ ex-
penses, the cost for the intervention increased to a mean
(SE) of €765 (33.5) per patient during the intervention
period.
Cost-utility
At conventional thresholds, decision-makers willingness
to pay around €40,000 the probability for the interven-
tion being cost-utile was estimated at 84%. Sensitivity
analyses showed that the cost-utility result was robust
(Fig. 2).
Discussion
The present analysis demonstrates that a pre-operative
8-week supervised exercise intervention was cost-
effective, showing a probability of 84% for decision-
makers willingness to pay around €40,000 for a QALY
gained. This is comparable to the typical threshold be-
tween £20,000 and £30,000 per QALY gained used by the
British National Health Service when instituting new
treatments.[34] Compared to care as usual, we found no
overall additional health care cost during the first post-
operative year despite adding 8 weeks of physiotherapist-
supervised exercise prior to TKR and THR surgery. In
return one can expect QALY gain over the following year.
This study is one of few RCTs that estimates costs and
cost-effectiveness of exercise as treatment in patients
with hip and knee OA, and, to our knowledge, the first
to analyse cost-utility of exercise prior to THR and TKR.
Previous cost-effectiveness analyses evaluating exercise,
as the only intervention and not prior to surgery, in pa-
tients with knee OA found better health outcomes at
lower costs, i.e. exercise was cost saving [13]. One RCT
found that water-based exercise saved £123-175 per pa-
tient per year despite a relatively high intervention cost
(£830 per patient) [35]. A second RCT found that both
aerobic and resistance training were cost saving, $114
and $117, respectively, along with improvements in self-
reported functioning [36]. A third RCT found QALY gains
of 0.023 (SE 0.04) from class-based exercise compared to
home-based exercise and a probability of 70% of being
cost-effective at a willingness to pay of £30.000 [37]. Fur-
ther, two RCTs have shown less total costs for patients
with hip OA and chronic knee pain, respectively, following
patient education and exercise programs compared to
usual care [38, 39]. Comparing our study of exercise prior
to OA surgery to studies evaluating exercise interventions
in other patient groups, the results are quite similar. A
Cochrane review of exercise for patients with heart failure
reported a QALY gain of 0.03 and a probability of 90% for
willingness to pay around 50.000 USD [40], group-based
exercise for the prevention of falling showed an incremen-
tal cost per QALY gain of 72.700 AUD [41], and pelvic-
floor muscle training showed cost-effectiveness with a
probability of >70% for the willingness to pay around
₤50.000 [42].
We found that patients allocated to exercise had a
lower total length of hospital stay and total cost during
the follow-up period. The results were not statistically
significant. However, should these findings not be due to
Table 2 Mean differences of QALYs and HOOS or KOOS for the 61-week follow-up period
Intervention (n = 84) Control (n = 81)
n Mean (SE) n Mean (SE) Mean difference (95% CI) ES
QALY, LTAPa 84 0.66 (0.04) 81 0.61 (0.04) 0.04 (0.01 to 0.07)
QALY, LTAPb 84 0.80 (0.01) 81 0.74 (0.01) 0.06 (0.02 to 0.09)
QALY, LOCFa 82 0.64 (0.05) 79 0.58 (0.05) 0.05 (0.02 to 0.09)
QALY, completea 63 0.68 (0.05) 59 0.63 (0.05) 0.05 (0.02 to 0.09)
QALY, per-protocola 62 0.63 (0.04) 81 0.59 (0.05) 0.04 (0.01 to 0.07)
HOOS/KOOS
ADL 84 35.9 (2.1) 81 32.1 (2.4) 3.80 (−2.45 to 10.07) 0.24
Pain 84 41.2 (2.2) 81 37.1 (2.4) 4.13 (−2.33 to 10.60) 0.29
Symptoms 84 33.9 (2.7) 81 32.2 (2.6) 1.69 (−5.79 to 9.17) 0.09
Sport and Recreation 84 33.1 (3.6) 81 26.3 (2.8) 6.79 (−2.10 to 15.69) 0.39
Quality of Life 84 43.4 (2.6) 81 35.2 (3.0) 8.25 (0.42 to 16.10) 0.59
Mean (bootstrap SE) and mean differences (95% confidence interval). ES, effect-size (mean difference/pooled standard deviation)
QALY, quality-adjusted life-years; complete, complete item response analysis; LTAP, linear trend at point; LCOF, last observation carried forward; per-protocol,
per-protocol analysis equals attending ≥12 exercise sessions. HOOS, Hip disability and Osteoarthritis Outcome Score; KOOS, Knee injury and Osteoarthritis Outcome
Score; ADL, function in daily living
aAdjusted for baseline EQ-5D-3 L scores
bUnadjusted analysis
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random variation, a reduction of 2.4 days in hospital per
patient and year is a relevant difference for the health
care system. In 2012, a total of 8787 and 8008 patients
underwent THR and TKR, respectively, at Danish hospi-
tals [43, 44]. Extrapolating the resource use to the
Danish THR and TKR population in 2012, exercise prior
to surgery could potentially save 39.500 days in hospital
per year. Seventy-five percent of all in hospital days dur-
ing the 61 week period were at orthopaedic units, leav-
ing 25% at other units. We did not ask the patients
about comorbidities, but the data show that at least
some had concurrent diseases. The second largest cost,
after admission to orthopaedic units, was admission to
internal medicine and cardiology units (Table 4). Over
half of the population with hip and knee OA have been
found to have concomitant cardiovascular disease and
86% of patients going through THR or TKR have one or
more comorbidities [45, 46]. There have also been found
significant associations between number and type of co-
morbidity and lower ADL, pain and HRQoL scores, with
largest impact on ADL in THR patients, suggesting that
functional limitations due to other diseases have to be
taken into account to optimize outcome after THR and
TKR [45, 46]. A national database study from Taiwan
found a reverse dose-relationship of having coronary ar-
tery disease and dyslipidemia in patients attending
physiotherapy due to symptoms from their OA, i.e. pa-
tients receiving a higher dose of physiotherapy showed a
lowered risk of coronary artery disease and dyslipidemia
[47]. Since comorbidities are common in OA and pos-
sibly can be influenced by the intervention given in our
study, we find the inclusion of the total cost and re-
source use important for this study (Table 3 and 4).
The sensitivity analyses showed that the health care
sector perspective using LTAP imputed data was robust
Table 3 Health care utilization during 61 weeks
Intervention
group (n = 84)
Control group
(n = 81)
Mean difference
(95% CI)
Intervention
Exercise sessions,
mean (range)
13.1 (0–24) 0 13.1 (12.2 to 14.0)
Primary health care, visits
General practice 18.2 (1.3) 19.5 (1.7) −1.36 (−5.46 to 2.74)
Physiotherapist 0.3 (0.1) 0.5 (0.2) −0.27 (−0.81 to 0.27)
Medical specialist 0.9 (0.2) 1.0 (0.2) −0.05 (−0.57 to 0.48)
Chiropractor 0 0.4 (0.03) −0.40 (−0.77 to −0.03)
Othera 2.0 (0.1) 2.2 (0.2) −0.28 (−0.72 to 0.16)
Subtotal 21.4 (1.3) 23.7 (1.7) −2.36 (−6.61 to 1.90)
Secondary health care, visits
Outpatient 8.4 (0.9) 8.5 (1.0) −0.13 (−2.80 to 2.55)
Emergency 0.2 (0.1) 0.5 (0.1) −0.24 (−0.52 to 0.03)
Subtotal 8.6 (0.9) 9.0 (1.1) −0.37 (−3.16 to 2.43)
Secondary health care, inhospital days
Orthopeadic 3.6 (0.4) 4.6 (1.1) −0.95 (−3.32 to 1.42)
Surgeryb 0.3 (0.1) 1.2 (0.7) −0.91 (−2.28 to 0.45)
Medicinec 0.7 (0.3) 0.8 (0.3) −0.12 (−0.92 to 0.68)
Oncologyd 0 0.4 (0.3) −0.37 (−0.95 to 0.22)
Other 0.3 (0.2) 0.3 (0.3) −0.01 (−0.72 to 0.70)
Subtotal 4.8 (0.7) 7.2 (1.8) −2.36 (−6.11 to 1.38)
Variables are expressed as the mean (bootstrap SE) number of outpatient visits
or in-hospital days per patient during the 61 week follow-up period and the
mean difference (95% confidence interval) between groups
aOther, includes visits at the dentistry, laboratory or foot care clinic
bSurgery, gastrointestinal, urology, plastic, thoracic
cMedicine, internal medicine, cardiology, medical gastroenterology, neurology,
geriatrics, general practice
dOther, includes inhospital stay at oftamology, odontology or
physiotherapy units
Table 4 Costs of the intervention, outpatient and emergency
visits and inpatient hospital stay during 61 weeks
Intervention
group (n = 84)
Control group
(n = 81)
Mean difference
(95% CI)
Intervention
Physiotherapy 326 (13) 0 326 (301 to 351)
Primary health care sector
General Practice 331 (28) 345 (29) −14 (−92 to 64)
Physiotherapist 22 (10) 98 (61) −76 (−197 to 45)
Specialists 99 (21) 97 (29) 2 (−68 to 72)
Chiropractor 2 (1) 6 (2) −4 (−9 to 0)
Othera 75 (7) 83 (8) −7 (−28 to 14)
Subtotal 530 (35) 629 (74) −99 (−258 to 60)
Secondary health care sector
Outpatient 2240 (560) 1917 (317) 323 (−933 to 1579)
Emergency 12 (4) 32 (11) −20 (−43 to 4)
Subtotal 2252 (557) 1949 (316) 303 (−949 to 1555)
Secondary health care sector
Orthopaedics 11760 (572) 11695 (1038) 66 (−2250 to 2382)
Surgeryb 280 (180) 773 (363) −493 (−1285 to 300)
Medicinec 883 (322) 865 (350) 18 (−919 to 955)
Oncology 0 213 (170) −213 (−547 to 120)
Otherd 150 (149) 189 (169) −40 (−494 to 415)
Subtotal 13074 (706) 13735 (1249) −662 (−3478 to 2154)
TOTAL 16181 (1174) 16313 (1374) −132 (−3668 to 3405)
Variables are expressed as the mean (bootstrap SE) per patient during the
61 week follow-up period and the mean difference (95% confidence interval)
between groups. The monetary units are presented in EUR2012
aOther, includes visits at the dentistry, laboratory or foot care clinic
bSurgery, gastrointestinal, urology, plastic, thoracic
cMedicine, internal medicine, cardiology, medical gastroenterology, neurology,
geriatrics, general practice
dOther, includes inhospital stay at oftamology, odontology or
physiotherapy units
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as compared to complete item response, unadjusted and
per-protocol analyses. The analysis using the health care
sector plus patients’ expenses differed slightly from the
base-case analysis showing a slightly lower probability
for willingness to pay thresholds. This was expected
since adding patients’ average expenses by €439 to the
average cost of the intervention (€326) would result in
higher costs for the intervention group, i.e. €765 versus
€326 for the intervention per patient calculated with or
without patient expenses, respectively. This study had a
follow-up period of 61 week. We did not find it neces-
sary to discount for costs or consequences as the study
only passed one year by 9 weeks. Implementation cost of
the intervention was not included in the analysis as the
intervention today is available at 377 private and public
physiotherapy clinics nationwide in Denmark [48].
Hence, the exercise program is already on the market in
Denmark and could be implemented as standard care
for patients undergoing THR or TKR without extra costs
for education and training of care providers.
With regards to generalisability of the cost-utility results
there are challenges in interpretation due to the vast differ-
ences in health care structure worldwide. In Denmark, all
health care utilization and cost for different services and
procedures performed in primary and secondary care are
registered in national registers [22, 23]. To enable com-
parison to other health care structures, the overall average
unit costs in this study can be found by dividing the cost
estimates in table 4 with the resource use in table 3 or by
viewing the tariff catalogues [49]. However, the efficacy of
the intervention is well documented and it is of general
interest to optimise the pre- as well as postoperative
period with increased activities of daily living and through
this a possible reduction in postoperative complications
(e.g. joint stiffness, thrombosis/emboli) and a faster return
to work for the younger part of this patient group.
Strength and limitations
Some strengths of this RCT were a rigorous design by ap-
plying the CONSORT recommendations [30], evaluating
Fig. 2 Cost effectiveness acceptability curves for incremental net monetary benefit to estimate the probability for the intervention being cost
effective at conventional thresholds for willingness to pay. Health care perspective, Health Care Sector perspective (base-case analysis); Complete
item response, only complete item response of the EQ-5D-3L included in the analysis; Health care & patients’ expenses, Health Care Sector and
patients’ own expenses perspective; No adjustment for baseline, adjustments for baseline EQ-5D-3L scores were not included; Per-protocol, only
patients attending 12 or more exercise sessions were included in the analysis
Fernandes et al. BMC Musculoskeletal Disorders  (2017) 18:5 Page 8 of 11
a time horizon of one year, in which changes in ADL and
HRQoL are expected to appear [50, 51], and using a com-
mon generic HRQoL measurement (EQ-5D-3L) to calcu-
late QALYs [52]. Our sample size of 165 allowed us
however to detect moderate, as opposed to small, effect
sizes. We found a significant effect size of 0.59 favouring
the exercise group in HOOS/KOOS quality of life, but the
effect size of 0.39 in HOOS/KOOS sport and recreation
function remained non-significant (Table 2). One limita-
tion of this RCT was that the Danish national registers do
not include costs for care delivered directly by the munici-
pality. In Denmark, the municipality is responsible for
post-operative care after hospital discharge, e.g. standard
post-operative exercise and home-care. Although group
allocation was stratified on municipality, differences in re-
source use and costs between the groups during the
follow-up period may exist. Another limitation was that
we had no data on patients’ work status (sick-leave, dis-
ability pension, retired or in the workforce) or OA-related
medicine. The majority of participants in this study were
assumed to be retired, as the retirement age in Denmark
is 65 years and the average age in the study was 67.5 years
at baseline. Even though the majority was assumed to be
retired, a recent study has shown that the year after THR
and TKR patients cost €6000 more compared to a refer-
ence population due to loss of employment income, use of
medication and need for home care [53]. A broader soci-
etal perspective including also work status, medication
and municipality-based services would therefore have
been optimal. If this intervention would be implemented
in routine clinical practice, the intervention could be pro-
vided in the primary care setting usually located within
15 km from peoples’ homes. The private pocket cost of
transportation would then be reduced whereas program
administration costs might increase and gains from econ-
omies of scale could be lost. This should be considered
and balanced with the potential benefit of extra participa-
tion and/or compliance by patients sensitive to provider
and/or transportation distance. Finally, of those meeting
eligibility criteria for this study only 30% were included
which may impact external validity.
Conclusion
Preoperative supervised neuromuscular exercise for
8 weeks was found to be cost-effective in patients sched-
uled for THR and TKR surgery at conventional thresh-
olds for willingness to pay. One-year clinical effects were
small to moderate and favoured the intervention group,
but only statistically significantly so for quality of life
measures.
Abbreviations
ADL: Activities of Daily Living; CEAC: Cost-Effectiveness Acceptability Curves;
CI: Confidence Interval; CONSORT: Consolidated Standards of Reporting Trials;
DKK: Danish Krona; EQ-5D-3L: European Quality of Life 5-Dimension 3-Level
Health Outcome; HOOS: Hip disability and Osteoarthritis Outcome Score;
HRQoL: Health Related Quality of Life; KOOS: Knee injury and Osteoarthritis
Outcome Score; LOCF: Last Observation Carried Forward; LTAP: Linear Trend
At Point; OA: Osteoarthritis; QALY: Quality Adjusted Life Year;
RCT: Randomised Controlled Trial; SD: Standard Deviation; SE: Standard Error;
THR: Total Hip Replacement; TKR: Total Knee Replacement; USD: US Dollar
Funding
This study was financed by research grants from OUH Svendborg Hospital
(nr. 12/9062) and the Association of Danish Physiotherapists’ Foundation for
research, CPD and professional development. The funders had no role in the
study design, data collection and analysis, decision to publish or preparation
of the manuscript.
Availability of data and materials
All data from the study are presented in the manuscript. We encourage the
sharing of data. Please contact the corresponding author if you wish to gain
access to data presented in this study.
Authors contribution
All authors were responsible for concept and design. LF and AV were
responsible of collection of data. LF was responsible for assembly of data
and drafting of the article. LF and RS were responsible for the analysis of
data. RS was responsible for statistical expertise. LF, RS, ER, AV and SO were
responsible for interpretation of data, critical revision of the article for
important intellectual content and for final approval of the article. LF and RS
take responsibility for the integrity of the work as a whole from inception to
finished article.
Competing interests
LF is co-owner of Ther-ex Ltd, Denmark . AV is co-owner of Ther-ex Ltd.,
Denmark. Ther-ex Ltd distribute (free of charge and commercial free) the
mobile application Ther-ex which offers functional and neuromuscular
exercise, exercise diary and pain monitoring for people with hip and knee
osteoarthritis. ER is developer of the Good Life with Osteoarthritis in
Denmark (GLA:D) program. GLA:D is a not-for-profit initiative to implement
clinical guidelines for osteoarthritis, hosted at the University of the Southern
Denmark. All other authors declare no competing interests.
Consent for publication
Not applicable.
Ethics and consent to participate
Informed written consent was obtained and the study was approved by
The Committee for Biomedical Research Ethics for the Region of Southern
Denmark, identifier: S-20090099 and the Danish Data Protection Agency,
identifier: 13/6464. The trial is registered at ClinicalTrials.gov (NCT01003756).
Author details
1Department of Orthopaedic Surgery and Traumatology, Odense University
Hospital, Odense, Denmark. 2Department of Rehabilitation, Odense University
Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark. 3Research Unit for
Musculoskeletal Function and Physiotherapy, Institute of Sports Science and
Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.
4Department of Clinical Research, University of Southern Denmark, Odense,
Denmark. 5Department of Public Health, Aarhus University, Aarhus, Denmark.
6Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Received: 8 June 2016 Accepted: 19 December 2016
References
1. Felson DT, Lawrence RC, Hochberg MC, McAlindon T, Dieppe PA, Minor MA,
Blair SN, Berman BM, Fries JF, Weinberger M, et al. Osteoarthritis: New
insights. Part 2: treatment approaches. Ann Intern Med. 2000;133(9):726–37.
2. Hawker GA, Badley EM, Borkhoff CM, Croxford R, Davis AM, Dunn S, Gignac
MA, Jaglal SB, Kreder HJ, Sale JE. Which patients are most likely to benefit
from total joint arthroplasty? Arthritis Rheum. 2013;65(5):1243–52.
3. Paulsen A, Roos EM, Pedersen AB, Overgaard S. Minimal clinically important
improvement (MCII) and patient-acceptable symptom state (PASS) in total
Fernandes et al. BMC Musculoskeletal Disorders  (2017) 18:5 Page 9 of 11
hip arthroplasty (THA) patients 1 year postoperatively. Acta Orthop.
2014;85(1):39–48.
4. Fransen M, McConnell S. Exercise for osteoarthritis of the knee. Cochrane
Database Syst Rev. 2008;4:CD004376.
5. Fransen M, McConnell S, Hernandez-Molina G, Reichenbach S. Exercise for
osteoarthritis of the hip. Cochrane Database Syst Rev. 2009;3:CD007912.
6. Lange AK, Vanwanseele B, Fiatarone Singh MA. Strength training for
treatment of osteoarthritis of the knee: a systematic review. Arthritis Care
Res. 2008;59(10):1488–94.
7. Fernandes L, Hagen KB, Bijlsma JW, Andreassen O, Christensen P,
Conaghan PG, Doherty M, Geenen R, Hammond A, Kjeken I, et al. EULAR
recommendations for the non-pharmacological core management of hip
and knee osteoarthritis. Ann Rheum Dis. 2013;72(7):1125–35.
8. Hernandez-Molina G, Reichenbach S, Bin Z, Lavalley M, Felson DT. Effect of
therapeutic exercise for hip osteoarthritis pain: results of a meta-analysis.
Arthritis Care Res. 2008;59(9):1221–8.
9. Juhl C, Christensen R, Roos EM, Zhang W, Lund H. Impact of exercise type
and dose on pain and disability in knee osteoarthritis: a systematic review
and meta-regression analysis of randomized controlled trials. Arthritis
Rheumatol. 2014;66(3):622–36.
10. Villadsen A, Overgaard S, Holsgaard-Larsen A, Christensen R, Roos EM.
Immediate efficacy of neuromuscular exercise in patients with severe
osteoarthritis of the hip or knee: a secondary analysis from a randomized
controlled trial. J Rheumatol. 2014;41(7):1385–94.
11. Wallis JA, Taylor NF. Pre-operative interventions (non-surgical and non-
pharmacological) for patients with hip or knee osteoarthritis awaiting joint
replacement surgery - a systematic review and meta-analysis. Osteoarthritis
Cartilage. 2011;19(12):1381–95.
12. Hoogeboom TJ, Oosting E, Vriezekolk JE, Veenhof C, Siemonsma PC,
de Bie RA, van den Ende CHM, van Meeteren NLU. Therapeutic validity
and effectiveness of preoperative exercise on functional recovery after
joint replacement: a systematic review and meta-analysis. PLoS ONE.
2012;7(5):e38031.
13. Pinto D, Robertson MC, Hansen P, Abbott JH. Cost-effectiveness of
Nonpharmacologic, nonsurgical interventions for Hip and/or knee
osteoarthritis: systematic review. Value Health. 2012;15(1):1–12.
14. Puig-Junoy J, Ruiz Zamora A. Socio-economic costs of osteoarthritis: a
systematic review of cost-of-illness studies. Semin Arthritis Rheum.
2015;44(5):531–41.
15. Kwok IH, Paton B, Haddad FS. Does Pre-operative physiotherapy improve
outcomes in primary total knee arthroplasty? - a systematic review.
J Arthroplasty. 2015;30(9):1657–63.
16. Villadsen A, Overgaard S, Holsgaard-Larsen A, Christensen R, Roos EM.
Postoperative effects of neuromuscular exercise prior to hip or knee
arthroplasty: a randomised controlled trial. Ann Rheum Dis. 2014;73(6):
1130–7.
17. Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD. Knee injury and
osteoarthritis outcome score (KOOS)–development of a self-administered
outcome measure. J Orthop Sports Phys Ther. 1998;28(2):88–96.
18. Roos EM, Toksvig-Larsen S. Knee injury and osteoarthritis outcome score
(KOOS) - validation and comparison to the WOMAC in total knee
replacement. Health Qual Life Outcomes. 2003;1:17.
19. Nilsdotter AK, Lohmander LS, Klassbo M, Roos EM. Hip disability and
osteoarthritis outcome score (HOOS)–validity and responsiveness in total
hip replacement. BMC Musculoskelet Disord. 2003;4:10.
20. Ageberg E, Link A, Roos EM. Feasibility of neuromuscular training in patients
with severe hip or knee OA: the individualized goal-based NEMEX-TJR
training program. BMC Musculoskelet Disord. 2010;11:126.
21. Ageberg E, Nilsdotter A, Kosek E, Roos EM. Effects of neuromuscular training
(NEMEX-TJR) on patient-reported outcomes and physical function in severe
primary hip or knee osteoarthritis: a controlled before-and-after study. BMC
Musculoskelet Disord. 2013;14:232.
22. Sahl Andersen J, De Fine ON, Krasnik A. The Danish national health service
register. Scand J Public Health. 2011;39(7 suppl):34–7.
23. Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register.
Scand J Public Health. 2011;39(7 suppl):30–3.
24. Gross and Disposable income by region, gender and age range, Table INDKP5.
http://www.statistikbanken.dk/statbank5a/default.asp?w=1920.
25. Roos EM, Lohmander LS. The knee injury and osteoarthritis outcome score
(KOOS): from joint injury to osteoarthritis. Health Qual Life Outcomes.
2003;1:64.
26. Peer MA, Lane J. The knee injury and osteoarthritis outcome score (KOOS): a
review of its psychometric properties in people undergoing total knee
arthroplasty. J Orthop Sports Phys Ther. 2013;43(1):20–8.
27. EuroQol Group; Oemar MO, M.: EQ-5D-3 L User Guide. Basic information on
how to use the EQ-5D-3 L instrument. . In. http://www.euroqol.org/; 2013.
28. Wittrup-Jensen KU, Lauridsen J, Gudex C, Pedersen KM. Generation of a
Danish TTO value set for EQ-5D health states. Scand J Public Health.
2009;37(5):459–66.
29. Efron BT, Tibshirani R. Bootstrap methods for standard errors, confidence
intervals and other measures of statistical accuracy. Stat Sci. 1986;1(1):54–77.
30. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated
guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.
31. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based
cost-effectiveness analysis: the importance of controlling for baseline utility.
Health Econ. 2005;14(5):487–96.
32. Hernández MAN, Vázquez-Polo FJ, González-Torre FJG, Bas EM. Complementing
the net benefit approach: a new framework for Bayesian cost-effectiveness
analysis. Int J Technol Assess Health Care. 2009;25(04):537–45.
33. Eichler H-G, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-
effectiveness analysis in health-care resource allocation decision-making:
How Are cost-effectiveness thresholds expected to emerge? Value Health.
2004;7(5):518–28.
34. The National Institute for Health and Care Excellence. How NICE measures
value for money in relation to public health interventions. 2013. https://
www.nice.org.uk/Media/Default/guidance/LGB10-Briefing-20150126.pdf.
35. Cochrane T, Davey R, Matthes Edwards S. Randomised controlled trial of the
cost-effectiveness of water-based therapy for lower limb osteoarthritis.
Health Technol Assess. 2005;9(31):130.
36. Sevick MA, Bradham DD, Muender M, Chen GJ, Enarson C, Dailey M,
Ettinger WH. Cost-effectiveness of aerobic and resistance exercise in seniors
with knee osteoarthritis. Med Sci Sports Exerc. 2000;32(9):1534–40.
37. Richardson G, Hawkins N, McCarthy CJ, Mills PM, Pullen R, Roberts C, Silman A,
Oldham JA. Cost-effectiveness of a supplementary class-based exercise
program in the treatment of knee osteoarthritis. Int J Technol Assess Health
Care. 2006;22(1):84–9.
38. Juhakoski R, Tenhonen S, Malmivaara A, Kiviniemi V, Anttonen T, Arokoski JP.
A pragmatic randomized controlled study of the effectiveness and cost
consequences of exercise therapy in hip osteoarthritis. Clin rehabil.
2011;25(4):370–83.
39. Hurley MV, Walsh NE, Mitchell H, Nicholas J, Patel A. Long-term outcomes
and costs of an integrated rehabilitation program for chronic knee pain:
a pragmatic, cluster randomized, controlled trial. Arthritis Care Res.
2012;64(2):238–47.
40. Rees K, Taylor RS, Singh S, Coats AJ, Ebrahim S. Exercise based rehabilitation
for heart failure. Cochrane Database Syst Rev. 2004;3:CD003331.
41. Church J, Goodall S, Norman R, Haas M. An economic evaluation of
community and residential aged care falls prevention strategies in NSW.
N S W Public Health Bull. 2011;22(3–4):60–8.
42. Imamura M, Abrams P, Bain C, Buckley B, Cardozo L, Cody J, Cook J, Eustice
S, Glazener C, Grant A, et al. Systematic review and economic modelling of
the effectiveness and cost-effectiveness of non-surgical treatments for
women with stress urinary incontinence. Health Technol Assess (Winch
Eng). 2010;14(40):1–188. iii-iv.
43. Dansk Hoftealloplastik Register. Årsrapport 2013. . In: Dækker fra 1 januar til
31december 2012 Opgørelseperiode fra 1 januar 2012 til 31 December 2012
Edited by Overgaard SP, A.B. www.dhr.dk; 2013.
44. Dansk Knæalloplastikregister. Årsrapport 2013. Administrativt ekstrakt. . In:
Kvalitetsindikatorer for operationer foretaget i perioden 2008–2012 Den
fulde rapport dækker perioden 01011997 – 31122012 Edited by Pedersen A,
B.; Haagen Hjelm, A.; Odgaard, A. www.dkar.dk; 2013.
45. Peter WF, Dekker J, Tilbury C, Tordoir RL, Verdegaal SHM, Onstenk R, Bénard
MR, Vehmeijer SB, Fiocco M, Vermeulen HM, et al. The association between
comorbidities and pain, physical function and quality of life following hip
and knee arthroplasty. Rheumatol Int. 2015;1–9.
46. Kirkness CS, Yu J, Asche CV. The effect on comorbidity and pain in patients
with osteoarthritis. J Pain Palliat Care Pharmacother. 2008;22(4):336–48.
47. Yeh HJ, Chou YJ, Yang NP, Cheng CC, Huang N. Physical therapy reduces
coronary artery disease and dyslipidemia among osteoarthritis patients: a
nationwide database study. Arch Phys Med Rehabil. 2015;97:8–16.
48. Skou ST, Odgaard A, Rasmussen JO, Roos EM. Group education and exercise
is feasible in knee and hip osteoarthritis. DanMed J. 2012;59(12):A4554.
Fernandes et al. BMC Musculoskeletal Disorders  (2017) 18:5 Page 10 of 11
49. Ministeriet for sundhed og forebyggelse. Takstsystem 2012. http://
sundhedsdatastyrelsen.dk/-/media/sds/filer/finansiering-og-afregning/
takster/2012/takstsystem2012.pdf. In.; 2012.
50. Vissers MM, Bussmann JB, Verhaar JAN, Arends LR, Furlan AD, Reijman M.
Recovery of physical functioning after total Hip arthroplasty: systematic
review and meta-analysis of the literature. Phys Ther. 2011;91(5):615–29.
51. Hopley CDJ, Crossett LS, Chen AF. Long-term clinical outcomes and
survivorship after total knee arthroplasty using a rotating platform knee
prosthesis: a meta-analysis. J Arthroplast. 2013;28(1):68–77. e63.
52. The National Institute for Health and Clinical Excellence. Methods for the
development of NICE public health guidance (third edition). In., 3rd edn.
https://www.nice.org.uk/process/pmg4/chapter/introduction; 2012.
53. Kjellberg J, Kehlet H: A nationwide analysis of socioeconomic outcomes
after hip and knee replacement. Dan Med J 2016, 63 (8).
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Fernandes et al. BMC Musculoskeletal Disorders  (2017) 18:5 Page 11 of 11
